AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 33 min read$SOPH

SOPHiA (SOPH) Q3 2026 Earnings Call Transcript

SOPHiA (SOPH) reported Q3 2026 earnings, highlighting 19% growth in platform analyses to 118,000. U.S. revenue grew 41%, driven by new accounts and expanding services. Liquid Biopsy tests saw 100% year-on-year growth. The company also announced collaborations with BioPharma firms, including a top 10 company for bladder cancer research and AstraZeneca for companion diagnostics.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 8:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 8:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
SOPHiA (SOPH) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$SOPHBullishMed
01

Why it matters

The disclosed growth metrics and new product traction provide fresh data that could influence investor sentiment and price action.

02

Market read

Strong earnings and pipeline updates make SOPHiA a notable mover in the health‑tech and biotech space.

03

What to watch

Potential regulatory hurdles for liquid biopsy and reimbursement uncertainties could temper upside.

Relevance 7/10Novelty 7/10Timing: post‑earnings today

Background

SOPHiA GENETICS presented its Q3 2026 earnings call, emphasizing network usage, U.S. revenue growth, new liquid biopsy test performance, and strategic collaborations.

Company-level read

Ticker impact

$SOPHBullishHigh confidence
Context

Q3 2026 earnings call disclosed 41% U.S. revenue growth, 118k analyses performed and new liquid biopsy product traction.

Expected impact

likely upward pressure as market prices in strong growth and new product adoption

Evidence & confidence

Revenue growth, new contracts and liquid biopsy expansion are fresh material that can drive the stock higher.

Market effects

Sector

Strengthens outlook for genomics and liquid biopsy sector.

Regional

Highlights U.S. market as primary growth driver for SOPHiA.

Global

Shows expanding adoption of AI‑driven diagnostics worldwide.

Counterpoint

What could challenge this read

If growth stalls outside the U.S., the stock could face pressure despite strong Q3 numbers.

Key entities

  • company
    SOPHiA GENETICS

    Provider of AI‑driven genomic analysis platforms.

  • partner
    AstraZeneca

    Collaborator on companion diagnostic programs.

Read at source← All news

Also covered by

1 outlet

Related articles

NOV 4
$SOPHMed

Sophia Genetics SA (SOPH) (Q3 2026) Earnings Call Highlights: Revenue Surges 25% with Strong

Sophia Genetics SA (SOPH) reported a 25% revenue surge in Q3 2026. CEO Ross Muken expects continued growth in 2027, driven by strong product momentum and a high backlog of customers. The company is investing in medical affairs to drive adoption and has secured notable biopharma collaborations, including with AstraZeneca. CFO George Cardoza emphasized profitability commitments and conservative guidance.

finance.yahoo.com7 min
NOV 3
$SOPHMed

SOPHiA GENETICS S.A. Q3 2026 Earnings Call Summary

SOPHiA GENETICS reported Q3 2026 U.S. revenue growth of 41%, driven by improved reimbursement and lower sequencing costs. Liquid Biopsy volume surged over 100% YoY, led by the MSK-ACCESS product. The company projects full-year 2026 revenue at the upper end of $94M-$96M range, with 2027 revenue highly visible. Management expects positive adjusted EBITDA in H2 2027. The Unified Patent Court rejected Guardant Health's appeal, confirming no injunction against MSK-ACCESS.

finance.yahoo.com2 min
NOV 3
$SOPHMed

SOPHiA GENETICS Q3 Earnings Call Highlights

SOPHiA GENETICS reported 551 core genomics customers, up from 488 a year earlier, with 30 new logos signed. CFO George Cardoza highlighted net dollar retention at 118% and annualized revenue churn below 1%. Growth was seen in HemOnc, Rare Disorders, and Solid Tumor testing, with MSK-IMPACT Flex adoption driving Solid Tumor growth. Liquid biopsy volume doubled year-over-year.

finance.yahoo.com6 min
NOV 3
$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q3 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September

SEC EDGAR 6-K3 min
AUG 11
$SOPHMedAI 8/10

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.

fool.com6 min